THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult a stockbroker or other registered dealer in securities, a bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in MicroPort NeuroScientific Corporation, you should at once hand this circular, together with the enclosed form of proxy, to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

MicroPort NeuroScientific Corporation

微創腦科學有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2172)

SCRIP DIVIDEND IN RELATION TO THE FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2025; PROPOSED RE-ELECTION OF DIRECTORS; PROPOSED RE-APPOINTMENT OF AUDITORS; PROPOSED GRANTING OF GENERAL MANDATES TO BUY BACK SHARES AND TO ISSUE SHARES AND NOTICE OF ANNUAL GENERAL MEETING

A notice convening the Annual General Meeting of MicroPort NeuroScientific Corporation to be held at 10:00 a.m. on Wednesday, 3 June 2026 at 1601 Zhangdong Road, Zhangjiang Hi-Tech Park, Shanghai, the People's Republic of China is set out on pages 25 to 29 of this circular. A form of proxy for use at the Annual General Meeting is also enclosed. Such form of proxy is also published on the websites of Hong Kong Exchanges and Clearing Limited (www.hkexnews.hk) and the Company (www.microportneurosci.com). Holders of treasury shares, if any, have no voting rights at the Annual General Meeting.

Whether or not you are able to attend the Annual General Meeting, please complete and sign the enclosed form of proxy in accordance with the instructions printed thereon and return it to the Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong as soon as possible but in any event not later than 10:00 a.m. on Monday, 1 June 2026 (Hong Kong Time). Completion and return of the form of proxy will not preclude Shareholders from attending and voting in person at the Annual General Meeting if they so wish.

7 May 2026

CONTENTS

Page

Definitions 1

Letter from the Board

1. Introduction 5
2. Scrip Dividend Scheme 5
3. Proposed Re-election of Directors 7
4. Proposed Re-appointment of Auditors 8
5. Proposed Granting of the Share Buy-back Mandate 9
6. Proposed Granting of the Issuance Mandate 9
7. Responsibility Statement 10
8. Annual General Meeting and Proxy Arrangement 10
9. Recommendation 11

Appendix I — Details of the Directors Proposed to be Re-elected at the Annual General Meeting 12

Appendix II — Explanatory Statement 21

Notice of Annual General Meeting 25

In this circular, unless the context otherwise requires, the following expressions shall have the following meanings:

"Annual General Meeting"	the annual general meeting of the Company to be held at 10:00 a.m. on Wednesday, 3 June 2026 at 1601 Zhangdong Road, Zhangjiang Hi-Tech Park, Shanghai, the People's Republic of China, to consider and, if appropriate, to approve the resolutions contained in the notice of the meeting which is set out on pages 25 to 29 of this circular, or any adjournment thereof
"Audit Committee"	the audit committee of the Company
"Board"	the board of Directors
"Company"	MicroPort NeuroScientific Corporation, an exempted company incorporated in the Cayman Islands, the shares of which are listed on the Main Board of the Stock Exchange (stock code: 2172)
"Director(s)"	the director(s) of the Company
"Final Dividend"	the proposed final dividend of HK$0.09 per Share for the year ended 31 December 2025
"Group"	the Company and its subsidiaries
"HK$"	Hong Kong dollars, the lawful currency of Hong Kong
"Hong Kong"	the Hong Kong Special Administrative Region of the People's Republic of China

"Issuance Mandate"	a general mandate proposed to be granted to the Directors to allot, issue or deal with additional Shares (including any sale or transfer of treasury shares out of treasury) of not exceeding 20% of the total number of Shares of the Company in issue (excluding treasury shares) as at the date of passing of the proposed ordinary resolution contained in item 6 of the notice of the Annual General Meeting as set out on pages 25 to 29 of this circular
"Latest Practicable Date"	30 April 2026, being the latest practicable date prior to the printing of this circular for ascertaining certain information in this circular
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange as amended from time to time
"Memorandum and Articles of Association"	the memorandum and articles of association of the Company currently in force
"Nomination Committee"	the nomination committee of the Company
"PRC"	the People's Republic of China
"Qualifying Shareholders"	the Shareholders whose registered addresses are in Hong Kong as shown on the register of members of the Company on the Record Date, other than Shareholder(s) whose name(s) appear(s) on the register of members of the Company on the Record Date and whose registered address(es) on that date is/are outside Hong Kong (if any) to whom the Directors, based on legal advice provided by legal advisers and on account either of legal restrictions under the laws of the relevant place or the requirements of the relevant regulatory body or stock exchange in that place, consider it necessary or expedient to exclude such Shareholder(s) from the Scrip Dividend Scheme
"Record Date"	8 July 2026, being the record date for determining the entitlement to the Final Dividend

"Remuneration Committee"	the remuneration committee of the Company
"RMB"	Renminbi, the lawful currency of the PRC
"Scrip Dividend Scheme"	the scheme proposed by the Directors in relation to the Final Dividend which offer the Qualifying Shareholders an alternative to elect to receive such dividend wholly or partly by an allotment and issue of new Shares credited as fully paid in lieu of cash payment
"Scrip Shares"	new Shares to be allotted and issued pursuant to the Scrip Dividend Scheme
"SFC"	the Securities and Futures Commission of Hong Kong
"SFO"	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)
"Share(s)"	ordinary share(s) of the Company
"Share Buy-back Mandate"	a general mandate proposed to be granted to the Directors to buy back Shares on the Stock Exchange of not exceeding 10% of the total number of Shares of the Company in issue (excluding treasury shares) as at the date of passing of the proposed ordinary resolution contained in item 5 of the notice of the Annual General Meeting as set out on pages 25 to 29 of this circular
"Shareholder(s)"	holder(s) of Share(s)
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"Takeovers Code"	the Codes on Takeovers and Mergers approved by the Securities and Futures Commission as amended from time to time
"treasury shares"	has the meaning ascribed to it under the Listing Rules
"%"	per cent

MicroPort NeuroScientific Corporation
微創腦科學有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2172)

Executive Directors:
Mr. Xie Zhiyong
Mr. Wang Yiqun Bruce

Non-executive Directors:
Dr. Zhang Jie *(Chairman)*
Mr. Liu Xudong
Ms. Wu Xia

Independent Non-executive Directors:
Dr. Zhang Haixiao
Mr. Fan Xin
Mr. Li Zhiyong
Mr. Liu Thomas A.

Registered Office:
Vistra (Cayman) Limited
P.O. Box 31119 Grand Pavilion
Hibiscus Way, 802 West Bay Road
Grand Cayman
KY1-1205
Cayman Islands

Head Office and Principal Place of Business in the PRC:
No. 1661 Zhangdong Road
Pudong New Area, Shanghai
PRC

Principal Place of Business in Hong Kong:
Room 1922, 19/F
Lee Garden One, 33 Hysan Avenue
Causeway Bay
Hong Kong

7 May 2026

To the Shareholders

Dear Sir/Madam,

SCRIP DIVIDEND IN RELATION TO THE FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2025;
PROPOSED RE-ELECTION OF DIRECTORS;
PROPOSED RE-APPOINTMENT OF AUDITORS;
PROPOSED GRANTING OF GENERAL MANDATES TO BUY BACK SHARES AND TO ISSUE SHARES
AND
NOTICE OF ANNUAL GENERAL MEETING

1. INTRODUCTION

The purpose of this circular is to provide you with information reasonably necessary to enable you to make decisions on whether to vote for or against the resolutions to be proposed at the Annual General Meeting for the approval of, among other matters (i) the payment of a Final Dividend (including the Scrip Dividend Scheme); (ii) the proposed re-election of the Directors; (iii) the proposed re-appointment of auditors; and (iv) the granting of a Share Buy-back Mandate and Issuance Mandate.

2. SCRIP DIVIDEND SCHEME

Reference is made to the announcement of the Company dated 25 March 2026 in relation to the annual results of the Company for the year ended 31 December 2025 (the "**Announcement**").

It was stated in the Announcement that the Directors had resolved to recommend the payment of a Final Dividend of HK$0.09 per Share for the year ended 31 December 2025 to the Shareholders whose names appear on the register of members of the Company on the Record Date and also to recommend the Scrip Dividend Scheme to the Qualifying Shareholders, subject to the approval of the Shareholders on the payment of Final Dividend at the Annual General Meeting and the grant by the Listing Committee of the Stock Exchange of the listing of, and permission to deal in, the Scrip Shares to be allotted and issued pursuant thereto.

In arriving at the decision to recommend the Scrip Dividend Scheme to the Qualifying Shareholders, the Directors consider that while the Company should declare a Final Dividend, the retention of cash, which would otherwise have been paid to the Shareholders as a cash dividend, within the Group would enhance the continuous growth, maintain the financial stability and reduce the financing costs of the Group. On the other hand, the Scrip Dividend Scheme will give those Qualifying Shareholders who wish to further invest in the Company the opportunity to increase their equity investment in the Company.

Qualifying Shareholders are entitled to elect to have the Final Dividend to be paid wholly or partly in Shares instead of in cash. Shareholders whose registered addresses are outside Hong Kong (if any) as shown in the register of members of the Company on the Record Date may not be permitted to participate in the Scrip Dividend Scheme if the Directors consider that the circulation of an offer of such election to such Shareholders would or might be unlawful or impracticable and accordingly no form of election will be sent to such Shareholders and they will receive the Final Dividend wholly in cash. The Company will make enquiry regarding the legal restrictions under the laws of the relevant place and the requirements of the relevant regulatory body or stock

exchange for considering whether to exclude such Shareholder from the Scrip Dividend Scheme and it may only exclude such Shareholder on the basis that, having made such enquiry, it would be necessary or expedient to do so.

For the purpose of calculating the number of Scrip Shares, the value of the Scrip Shares will be fixed by the Board at its discretion with reference to the average of the closing prices of the Shares on the Stock Exchange for the five consecutive trading days ending on (and including) the Record Date less a discount of 10% (the "**10% Discount**") of such average price or the par value of Shares, whichever is higher. In determining the price at which the Scrip Shares will be issued, the Board will take into consideration the average closing price of the Shares for the five trading days immediately preceding the Record Date and market conditions. While the Company considers that a Final Dividend should be declared, the retention of the cash destined for payment of the Final Dividend could improve the financial stability of the Group and reduce the financing costs of the operation of the Group. As such, the Company is offering the 10% Discount in order to encourage more Qualifying Shareholders to take up the Scrip Shares as alternative in receiving their dividends.

The number of Scrip Shares to be issued will be rounded down to the nearest whole number of Scrip Shares and no Qualifying Shareholder is entitled to be allotted and issued any fraction of a Scrip Share under the Scrip Dividend Scheme. Fractional entitlements to Scrip Shares will be aggregated and sold for the benefit of the Company.

The Scrip Shares will rank pari passu in all respects with the Shares in issue on the date of allotment and issue of the Scrip Shares save that they will not be entitled to the Final Dividend for the year ended 31 December 2025.

On the condition that the payment of the above Final Dividend by way of the Scrip Dividend Scheme is approved by the Shareholders at the Annual General Meeting, a circular containing details of the Scrip Dividend Scheme, together with a form of election (to the Qualifying Shareholders only), will be despatched to the Shareholders on or about Thursday, 23 July 2026.

Subject to the passing of the resolution concerned at the Annual General Meeting, application will be made to the Listing Committee of the Stock Exchange for the listing of, and permission to deal in, the Scrip Shares. No part of the Scrip Shares will be listed or dealt in on any stock exchange other than the Stock Exchange, and no such listing or permission to deal is being or is proposed to be sought.

Closure of register of members

In order to determine the entitlement to the proposed Final Dividend, the register of members of the Company will be closed from Monday, 6 July 2026 to Wednesday, 8 July 2026, both days inclusive, during which period no transfer of shares will be registered. The record date for the proposed final dividend is 8 July 2026. In order to qualify for the proposed Final Dividend, all transfers of shares, accompanied by the relevant share certificates, must be lodged with the Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong, for registration not later than 4:30 p.m. on Friday, 3 July 2026 (Hong Kong time), being the last registration date.

Subject to the approval by the Shareholders of the payment of a Final Dividend at the Annual General Meeting and the grant by the Listing Committee of the Stock Exchange of the listing of, and permission to deal in, the Scrip Shares on the Stock Exchange, the proposed Final Dividend is expected to be paid on or about Friday, 21 August 2026. Dividend warrants and share certificates for new shares to be issued under the Scrip Dividend Scheme will be despatched to the Shareholders by ordinary mail on or about Friday, 21 August 2026. The dealings in the Scrip Shares on the Stock Exchange are expected to commence on or around Monday, 24 August 2026.

3. PROPOSED RE-ELECTION OF DIRECTORS

In accordance with Article 26.3 of the Memorandum and Articles of Association, any director appointed shall hold office only until the first annual general meeting of the Company after the Director's appointment and shall then be eligible for re-election at that meeting. Accordingly, Dr. Zhang Jie, Mr. Liu Xudong and Mr. Liu Thomas A. shall retire at the Annual General Meeting, and, being eligible, offered themselves for re-election at the Annual General Meeting.

In accordance with Article 26.4 of the Memorandum and Articles of Association, one-third of the Directors for the time being (or, if their number is not a multiple of three, then the number nearest to, but not less than, one-third) shall be subject to retirement by rotation at least once every three years. Any Directors required to stand for re-election pursuant to Article 26.3 shall not be taken into account in determining the number of Directors and which Directors are to retire by rotation. Accordingly, Mr. Xie Zhiyong and Ms. Wu Xia shall retire at the Annual General Meeting, and, being eligible, offer themselves for re-election at the Annual General Meeting.

The Nomination Committee has reviewed the structure and composition of the Board, the confirmations and disclosures given by the Directors, the qualifications, skills and experience, time commitment and contribution of the retiring Directors with reference to the nomination principles and criteria set out in the Company's board diversity policy and director nomination policy and the Company's corporate strategy, and the independence of all independent non-executive Directors. The Nomination Committee has recommended to the Board on the re-election of the aforementioned retiring Directors. Mr. Liu Thomas A. has given confirmation of his independence pursuant to Rule 3.13 of the Listing Rules. The Company considers that Mr. Liu Thomas A. is independent in accordance with the independence guidelines set out in the Listing Rules and will continue to bring valuable business experience, knowledge and professionalism to the Board for its efficient and effective functioning and diversity.

Details of the Directors proposed for re-election at the Annual General Meeting are set out in Appendix I to this circular.

4. PROPOSED RE-APPOINTMENT OF AUDITORS

In accordance with Rule 13.88 of the Listing Rules, an ordinary resolution will be proposed at the Annual General Meeting (1) to re-appoint KPMG; and (2) to re-appoint KPMG Huazhen LLP as the overseas and domestic auditors of the Company for the year 2026 and until the next annual general meeting of the Company, to provide 2026 annual financial report audit services or other related consultancy services, and to authorize the Board to fix their remuneration. The estimated audit fee ("**Estimated Audit Fee**") for the audit of the consolidated financial statements of the Group for the financial year ending 31 December 2026 is expected to be in the range of approximately RMB2.79 million to RMB2.94 million. The Estimated Audit Fee is considered fair and reasonable, having been determined after due consideration and arm's length negotiation between the Company and KPMG. In arriving at the Estimated Audit Fee, the Company has taken into account a number of factors, including the size and structure of the Group, the nature and complexity of the Group's businesses, the expected scope, timetable and direction of the audit, and the time and resources deployed by the auditor. Furthermore, the Estimated Audit Fee assumes there will be no material changes in the Group's businesses and operations, accounting policies or regulatory environment, and that the Company will provide timely and adequate assistance and information as required for the purpose of the audit.

The appointment of the auditors of the Company has been reviewed by the Audit Committee which made recommendation to the Board that the appointment be submitted and proposed for Shareholders' approval at the Annual General Meeting. As KPMG is relatively familiar with the Group's financials and affairs, the Board considers that the audit and other related work in respect of the Group for the year ending 31 December 2026 could be performed more efficiently by KPMG, which is in the best interests of the Company and the Shareholders as a whole.

5. PROPOSED GRANTING OF THE SHARE BUY-BACK MANDATE

In order to give the Company the flexibility to buy back Shares if and when appropriate, an ordinary resolution will be proposed at the Annual General Meeting to approve the granting of the Share Buy-back Mandate to the Directors to buy back Shares on the Stock Exchange of not exceeding 10% of the total number of issued Shares (excluding treasury shares) as at the date of passing of the proposed ordinary resolution contained in item 5 of the notice of the Annual General Meeting as set out on pages 25 to 29 of this circular (i.e. a total of 57,567,080 Shares on the basis that the issued share capital of the Company (excluding treasury shares) remains unchanged on the date of the Annual General Meeting). The Directors wish to state that they have no immediate plan to buy back any Shares pursuant to the Share Buy-back Mandate. An explanatory statement required by the Listing Rules to provide the Shareholders with requisite information reasonably necessary for them to make an informed decision on whether to vote for or against the granting of the Share Buy-back Mandate is set out in Appendix II to this circular.

6. PROPOSED GRANTING OF THE ISSUANCE MANDATE

In order to give the Company the flexibility to issue Shares (including any sale or transfer of treasury shares) if and when appropriate, an ordinary resolution will be proposed at the Annual General Meeting to approve the granting of the Issuance Mandate to the Directors to allot, issue or deal with additional Shares (including any sale or transfer of treasury shares out of treasury) of not exceeding 20% of the total number of issued Shares (excluding treasury shares) as at the date of passing of the proposed ordinary resolution contained in item 6 of the notice of the Annual General Meeting as set out on pages 25 to 29 of this circular (i.e. a total of 115,134,161 Shares on the basis that the issued share capital of the Company (excluding treasury shares) remains unchanged). An ordinary resolution to extend the Issuance Mandate by adding the number of Shares bought back by the Company pursuant to the Share Buy-back Mandate will also be proposed at the Annual General Meeting.

7. RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this document misleading.

8. ANNUAL GENERAL MEETING AND PROXY ARRANGEMENT

The notice of the Annual General Meeting is set out on pages 25 to 29 of this circular.

Pursuant to the Listing Rules and the Memorandum and Articles of Association, any vote of Shareholders at a general meeting must be taken by poll except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands. Article 19.7 of the Memorandum and Articles of Association provides that, at any general meeting a resolution put to the vote of the meeting shall be decided on a poll. According to Article 20.1 of the Memorandum and Articles of Association, every shareholder present in person or by proxy shall have one vote for each share registered in his name in the register. An explanation of the detailed procedures of voting by poll will be provided to the Shareholders at the Annual General Meeting. The Company will publish an announcement of the poll results on the websites of the Stock Exchange and the Company after the Annual General Meeting in accordance with Rule 13.39(5) of the Listing Rules.

A form of proxy for use at the Annual General Meeting is enclosed with this circular and such form of proxy is also published on the websites of Hong Kong Exchanges and Clearing Limited (www.hkexnews.hk) and the Company (www.microportneurosci.com). To be valid, the form of proxy must be completed and signed in accordance with the instructions printed thereon and deposited, together with the power of attorney or other authority (if any) under which it is signed or a certified copy of that power of attorney or authority at the Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong as soon as possible but in any event not later than 10:00 a.m. on Monday, 1 June 2026 (Hong Kong time). Completion and delivery of the form of proxy will not preclude you from attending and voting at the Annual General Meeting if you so wish and in such event, your proxy form shall be deemed to be revoked.

9. RECOMMENDATION

The Directors consider that the resolutions in relation to, among others, (i) the payment of a Final Dividend (including the Scrip Dividend Scheme); (ii) the proposed re-election of the Directors; (iii) the proposed re-appointment of auditors; and (iv) the granting of a Share Buy-back Mandate and Issuance Mandate are in the best interests of the Company and the Shareholders. Accordingly, the Directors recommend the Shareholders to vote in favour of the relevant resolutions to be proposed at the Annual General Meeting.

Yours faithfully,
By Order of the Board
MicroPort NeuroScientific Corporation
Dr. Zhang Jie
Chairman and Non-executive Director

The following are details of the Directors being eligible, offer themselves for re-election at the Annual General Meeting.

(1) DR. ZHANG JIE

Position and experience

Dr. Zhang, born in 1979, was appointed as a non-executive Director and Chairman of the Board on 14 November 2025. He is also the chairperson of the strategic committee of the Company and a member of the remuneration committee of the Company.

Dr. Zhang is the Chief Technology Officer of the Greater China region of MicroPort Scientific Corporation ("**MicroPort**", a company listed on the Hong Kong Stock Exchange, stock code: 853). As an Outstanding Technical Leader in Shanghai, he also provides in-house mentorship for postgraduates at Zhejiang University, East China University of Science and Technology and University of Shanghai for Science and Technology. Dr. Zhang joined MicroPort in 2007. As the principal researcher and key inventor of technologies for the Firehawk® Stent, Dr. Zhang effectively overcame complex technological challenges and secured several invention patents both domestically and internationally. Since joining MicroPort, Dr. Zhang has played a crucial role in the development of new technologies and products. He has spearheaded R&D efforts across multiple businesses within MicroPort, while incubating emerging products in the areas of ophthalmology, otorhinolaryngology, dentistry and medical cosmetology. Dr. Zhang has amassed multiple innovations over the past 17 years, secured the First Prize of the Shanghai Scientific and Technological Progress Awards and the Silver Prize of the China Patent Award, and now has 53 domestic and international authorized patents.

Dr. Zhang received his bachelor's degree in communication engineering from Zhejiang University of Technology in 2002, his master's degree in Test and Measurement Technology and Instrumentation in 2007, and his Ph.D. in Biomedical Engineering in 2021, both from University of Shanghai for Science and Technology.

Length of service and director's emoluments

Dr. Zhang has entered into a letter of appointment with the Company for an initial term of three years commencing on 14 November 2025, subject to rotation and re-election at annual general meetings in accordance with the Articles of Association of the Company. Pursuant to the appointment letter, Dr. Zhang will not receive any emolument for serving as a non-executive Director.

Relationships

Save as disclosed above, Dr. Zhang does not have any relationship with any Directors, senior management, substantial shareholders (as defined in the Listing Rules) or controlling shareholders (as defined in the Listing Rules) of the Company.

Interest in Shares

As at the Latest Practicable Date, Dr. Zhang had the following interests in shares or underlying shares of the Company and its associated corporations pursuant to Part XV of the SFO:

Name of the Company/ associated corporations	Number of shares held	Number of underlying shares	Total number of shares/ underlying shares held	Approx. Percentage of the issued share capital of the Company/ associated corporations
The Company	63,212	—	63,212	0.01%

Save as disclosed above, Dr. Zhang was not interested or deemed to be interested in shares, underlying shares or debentures of the Company or its associated corporation pursuant to Part XV of the SFO.

(2) MR. XIE ZHIYONG

Position and experience

Mr. Xie, born in 1976, was appointed as our Director on 2 November 2020 and re-designated as our executive Director on 16 December 2021. He joined our Group in April 2012 and has been serving as our president since then. He was appointed as chief executive officer in January 2024 and is mainly responsible for the overall management of our Group. He is also a member of the nomination committee of the Company, the strategic committee of the Company and the commercialization committee of the Company. Mr. Xie also holds various directorships and management positions in our Group companies including a director and general manager of MicroPort NeuroTech (Shanghai) Co., Ltd. ("**MicroPort Neuro**") since May 2012, and was appointed as Chairman of the Board from November 2023.

Mr. Xie had over 27 years of experience in the neuro-intervention industry. Prior to joining our Group, from January 1999 to March 2012, Mr. Xie successively served as a R&D engineer, a manager of the stent R&D department and a R&D director at Shanghai MicroPort Medical, where he was primarily responsible for R&D of coronary stents, peripheral vascular products and neuro-interventional products including leading the R&D work for APOLLO™ Intracranial Stent System ("**APOLLO™ Intracranial Stent**"). Mr. Xie was awarded the Second Prize for National Science and Technology Award (國家科學技術進步獎二等獎) by the State Council in February 2007 and December 2014, the First Prize and Second Prize for the Science and Technology Award of Shanghai (上海市科學技術獎一等獎及二等獎) by the Shanghai Municipal Government in November 2009, the Second Prize for the Science and Technology Award of Shanghai Pudong New Area (上海市浦東新區科技進步獎二等獎) by the People's Government of Shanghai Pudong New Area in January 2017, and the First Prize for the Science and Technology Award of Shanghai (上海市科學技術獎一等獎) by the Shanghai Municipal Government in December 2020. He was also recognised as a Zhangjiang Professional of Excellence (張江卓越人才) by the Management Committee of Shanghai Zhangjiang Hi-Tech Park (上海市張江高科園區管理委員會) in July 2017, a Leading Talent of Shanghai (上海市領軍人才) by the Organization Department of CPC Shanghai Committee (中共上海市委組織部) and Shanghai Municipal Human Resources and Social Security Bureau (上海市人力資源和社會保障局) in February 2020 and a Senior Engineer (正高級工程師) by the Shanghai Municipal Human Resources and Social Security Bureau (上海市人力資源和社會保障局) in December 2020. He has 100 authorized patents in China and overseas, presided over nine provincial and ministerial projects, and led the research and development of neuro-interventional medical devices, of which two were admitted to the "Green Path" of the NMPA and four were rated as innovative products in Shanghai.

Mr. Xie graduated from Shanghai Jiao Tong University (上海交通大學) in the PRC with a major in communications engineering in July 2004 and obtained his master's degree in project management from Zhejiang University (浙江大學) in the PRC in June 2011.

Length of service and director's emoluments

Mr. Xie has entered into a service contract with the Company for an initial term of three years commencing from 16 December 2021 and will continue thereafter, subject to retirement by rotation and re-election in accordance with the Memorandum and Articles of Association and the Listing Rules, and is subject to termination as provided in the service contract. Pursuant to the service contract, Mr. Xie is not entitled to receive director's fee from the Company.

Relationships

Save as disclosed above, Mr. Xie does not have any relationship with any Directors, senior management, substantial shareholders (as defined in the Listing Rules) or controlling shareholders (as defined in the Listing Rules) of the Company.

Interest in Shares

As at the Latest Practicable Date, Mr. Xie had the following interests in shares or underlying shares of the Company and its associated corporations pursuant to Part XV of the SFO:

Name of the Company/ associated corporations	Number of shares held	Number of underlying shares	Total number of shares/ underlying shares held	Approx. Percentage of the issued share capital of the Company/ associated corporations
The Company	—	1,625,775 *(Note 1)*	1,625,775	0.28%

Note:

1. Mr. Xie was interested in: (i) 881,775 underlying shares of the Company by virtue of the Award Shares (as defined in the Company's 2025 Annual Report); and (ii) 744,000 underlying shares of the Company by virtue of options granted to him under the Company's share scheme(s).

Save as disclosed above, Mr. Xie was not interested or deemed to be interested in shares, underlying shares or debentures of the Company or its associated corporation pursuant to Part XV of the SFO.

(3) MR. LIU XUDONG

Position and experience

Mr. Liu, born in 1975, was appointed as a non-executive Director on 14 November 2025. He is also the member of the commercialization committee of the Company. Mr. Liu is the executive deputy general manager of Shanghai MicroPort Weilian Weitong Health Management Co., Ltd.* (上海微創微聯微通健康管理有限公司).

Mr. Liu has nearly 25 years of marketing experience in the healthcare sector and more than 15 years of experience managing marketing teams. From 2005 to 2023, Mr. Liu worked at Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (a company listed on the Shenzhen Stock Exchange, stock code: 300760.SZ, "**Mindray**"), primarily responsible for sales and successively served as regional manager, senior regional manager and department head. In 2024, Mr. Liu worked at Shanghai BioGerm Medical Technology Co., Ltd. as deputy general manager of marketing, where he assumed overall responsibility for the sales, marketing, technical support and commercial departments, and led the upgrade of the sales system and reconstruction of the distribution channels.

Mr. Liu received his bachelor's degree in marketing from Shandong University in 2005, and MBA degree from Capital University of Economics and Business in 2008.

Length of service and director's emoluments

Mr. Liu has entered into a letter of appointment with the Company for an initial term of three years commencing on 14 November 2025, subject to rotation and re-election at annual general meetings in accordance with the Articles of Association of the Company. Pursuant to the appointment letter, Mr. Liu will not receive any emolument for serving as a non-executive Director.

Relationships

Save as disclosed above, Mr. Liu does not have any relationship with any Directors, senior management, substantial shareholders (as defined in the Listing Rules), or controlling shareholders (as defined in the Listing Rules) of the Company.

Interest in Shares

As at the Latest Practicable Date, Mr. Liu was not interested or deemed to be interested in shares, underlying shares of debentures of the Company or its associated corporation pursuant to Part XV of the SFO.

(4) MS. WU XIA

Position and experience

Ms. Wu, born in 1981, was appointed as our Director on 19 November 2021 and was re-designated as our non-executive Director on 16 December 2021. She is primarily responsible for overseeing the management and operations of our Group.

Ms. Wu has over 14 years of experience in research and private equity investment focusing on healthcare industry. Ms. Wu joined CICC Jia Cheng Investment Management Company Limited (中金佳成投資管理有限公司) in July 2008 and served as vice president from January 2012 to December 2014 and as executive director from January 2015 to August 2018. Ms. Wu transferred into CICC Capital Management Co., Ltd. (中金資本運營有限公司) ("**CICC Capital**") in August 2018 as an executive director and has been serving as a managing director of CICC Capital since January 2019, where she is primarily responsible for the overall investment and management of CICC Kangrui I (Ningbo) Equity Investment Limited Partners (Limited Partnership) (中金康瑞壹期(寧波)股權投資基金合夥企業(有限合夥)). Ms. Wu has also been serving as a director of Genetron Holdings Limited, a company whose shares are listed on the NASDAQ under the trading symbol of "GTH" and delisted in March 2024, since September 2017, and a non-executive director of MicroPort CardioFlow Medtech Corporation (微創心通醫療科技有限公司), a medical device company whose shares are listed on the Stock Exchange (stock code: 2160). She was awarded "Outstanding Young PE Investor of the Year 2018" by China Renaissance (華興資本) in 2018.

Ms. Wu obtained her bachelor's degree in finance from Peking University (北京大學) in the PRC in July 2003 and her master's degree in economics and finance from the University of Warwick in the United Kingdom in January 2005.

Length of service and director's emoluments

Ms. Wu has entered into an appointment letter with the Company for an initial term of three years commencing from 16 December 2021 and will continue thereafter, subject to retirement by rotation and re-election in accordance with the Memorandum and Articles of Association and the Listing Rules, and is subject to termination as provided in the appointment letter. Pursuant to the appointment letter, Ms. Wu is not entitled to receive director's fee from the Company.

Relationships

Save as disclosed above, Ms. Wu does not have any relationship with any Directors, senior management, substantial shareholders (as defined in the Listing Rules) or controlling shareholders (as defined in the Listing Rules) of the Company.

Interest in Shares

As at the Latest Practicable Date, Ms. Wu was not interested or deemed to be interested in shares, underlying shares of debentures of the Company or its associated corporation pursuant to Part XV of the SFO.

(5) MR. LIU THOMAS A.

Position and experience

Mr. Liu, born in 1964, was appointed as the independent non-executive Director on 29 December 2025. He is also a member of the audit committee, strategic committee and commercialization committee of the Company.

Mr. Liu is a seasoned executive with over 30 years of senior leadership experience in supply chain logistics, manufacturing, industrial automation, risk management, and operations across Asia Pacific, North America, and Europe. He currently serves as a senior advisor of China Harbour Engineering Company Limited and Investment Committee member of Hong Kong Science and Technology Parks Corporation. From August 2022 to August 2023, Mr. Liu served as an independent director of GigaCloud Technology Inc. (a company listed on NASDAQ, stock symbol: GCT). From September 2020 to December 2023, Mr. Liu served as the President of Greater China of Prologis Inc., overseeing operations, business development, capital deployment, venture capital investment, and mergers and acquisitions. Prior to these roles, from September 2014 to March 2020, Mr. Liu served as Head of Wanda Capital, overseeing capital deployment, strategic acquisition, fundraising and risk management for Dalian Wanda Group, a cross-industry

multinational conglomerate. Furthermore, Mr. Liu's earlier roles include managing director at Blue Ridge Capital from August 2009 to September 2014, where he led operational value-add initiatives and fundraising, and a managing director at Honeywell Greater China from June 2006 to August 2009, where he propelled the company's substantial revenue growth. Mr. Liu also held leadership positions at Lear Corporation and Johnson Controls, driving significant growth in automotive and manufacturing sectors.

Mr. Liu received his bachelor's degree in manufacturing systems engineering from GMI Engineering & Management Institute (currently known as Kettering University) in September 1989, his master's degree in systems design engineering from University of Waterloo in April 1992 and his EMBA degree in finance and investment from Cheung Kong Graduate School of Business in April 2012.

Relationships

Save as disclosed above, Mr. Liu does not have any relationship with any Directors, senior management, substantial shareholders (as defined in the Listing Rules) or controlling shareholders (as defined in the Listing Rules) of the Company.

Length of service and director's emoluments

Mr. Liu has entered into a letter of appointment with the Company for an initial term of three years commencing from 29 December 2025 and will hold office until the next general meeting of the Company following his appointment and be entitled for re-election at annual general meetings in accordance with the articles of association of the Company. Mr. Liu is entitled to a director's fee of RMB200,000 per annum, which is determined with reference to the fees paid by comparable companies, time, commitment, responsibilities of Mr. Liu and the Company's performance.

Interest in Shares

As at the Latest Practicable Date, Mr. Liu was not interested or deemed to be interested in shares, underlying shares of debentures of the Company or its associated corporation pursuant to Part XV of the SFO.

GENERAL

There is no information in relation to each of Dr. Zhang Jie, Mr. Xie Zhiyong, Mr. Liu Xudong, Ms. Wu Xia and Mr. Liu Thomas A. which is disclosable nor is Dr. Zhang Jie, Mr. Xie Zhiyong, Mr. Liu Xudong, Ms. Wu Xia and Mr. Liu Thomas A. involved in any of the matters

required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to (v) of the Listing Rules and there are no other matters concerning the re-election of Dr. Zhang Jie, Mr. Xie Zhiyong, Mr. Liu Xudong, Ms. Wu Xia and Mr. Liu Thomas A. that need to be brought to the attention of the Shareholders.

1. SHARE CAPITAL

As at the Latest Practicable Date, the issued share capital of the Company comprised 575,670,809 Shares (excluding treasury shares) and the Company has 9,364,000 treasury shares.

Subject to the passing of the ordinary resolution set out in item 5 of the notice of the Annual General Meeting in respect of the granting of the Share Buy-back Mandate and on the basis that the issued share capital of the Company (excluding treasury shares) remains unchanged on the date of the Annual General Meeting, i.e. being 575,670,809 Shares, the Directors would be authorized under the Share Buy-back Mandate to buy back, during the period in which the Share Buy-back Mandate remains in force, a total of 57,567,080 Shares, representing 10% of the total number of Shares in issue (excluding treasury shares) as at the date of the Annual General Meeting.

2. REASONS FOR SHARE BUY-BACK

The Directors believe that the granting of the Share Buy-back Mandate is in the best interests of the Company and the Shareholders as a whole.

When exercising the Share Buy-back Mandate, the Directors may, subject to market conditions and the Company's capital management needs at the relevant time of the buy-backs, resolve to cancel the Shares bought back following settlement of any such buy-back or hold them as treasury shares. Shares bought back for cancellation may, depending on the market conditions and funding arrangements at the time, lead to an enhancement of the net asset value per Share and/or earnings per Share. On the other hand, Shares bought back and held by the Company as treasury shares may be resold on the market at market prices to raise funds for the Company, or transferred or used for other purposes, and subject to compliance with the Listing Rules, the Memorandum and Articles of Association, and the laws of the Cayman Islands, Share buy-backs will only be made when the Directors believe that such a buy-back will benefit the Company and the Shareholders.

3. FUNDING OF SHARE BUY-BACK

Share buy-backs pursuant to the Share Buy-back Mandate would be financed entirely from the Company's available cash flow or working capital facilities. The Company may only apply funds legally available for Shares buy-back in accordance with its Memorandum and Articles of Association, the laws of the Cayman Islands and/or any other applicable laws, as the case may be.

4. IMPACT OF SHARE BUY-BACK

There might be a material adverse impact on the working capital or gearing position of the Company (as compared with the position disclosed in the audited accounts contained in the annual report of the Company for the year ended 31 December 2025) in the event that the Share Buy-back Mandate was to be carried out in full at any time during the proposed buy-back period. However, the Directors do not intend to exercise the Share Buy-back Mandate to such extent as would, in the circumstances, have a material adverse effect on the working capital requirements of the Company or the gearing levels which in the opinion of the Directors are from time to time appropriate for the Company.

5. MARKET PRICES OF SHARES

The highest and lowest prices at which the Shares had been traded on the Stock Exchange during each of the previous 12 months up to and including the Latest Practicable Date were as follows:

Month	**Highest** *HK$*	**Lowest** *HK$*
2025		
May	11.34	9.91
June	19.06	9.88
July	14.96	11.94
August	16.44	12.60
September	14.60	11.84
October	12.88	11.09
November	12.12	9.96
December	11.27	10.07
2026		
January	14.53	11.08
February	12.37	11.03
March	11.93	10.12
April *(up to the Latest Practicable Date)*	11.45	10.11

6. GENERAL

To the best of their knowledge and having made all reasonable enquiries, none of the Directors nor any of their respective close associates (as defined in the Listing Rules) have any present intention to sell any Shares to the Company in the event that the granting of the Share Buy-back Mandate is approved by the Shareholders.

The Company has not been notified by any core connected persons (as defined in the Listing Rules) of the Company that they have a present intention to sell any Shares to the Company, or that they have undertaken not to sell any Shares held by them to the Company in the event that the granting of the Share Buy-back Mandate is approved by the Shareholders.

The Directors will exercise the power of the Company to repurchase Shares pursuant to the Share Buy-back Mandate in accordance with the Listing Rules and the applicable laws of the Cayman Islands and the Memorandum and Articles of Association.

The Company has confirmed that neither the explanatory statement nor the proposed share buy-back has any unusual features.

The Company confirms that the explanatory statement set out in this Appendix II contains the information required under Rule 10.06(1)(b) of the Listing Rules and that neither the explanatory statement nor the proposed share repurchase has unusual features. Following a repurchase of Shares, the Company may cancel any repurchased Shares and/or hold them as treasury shares subject to, among others, market conditions and its capital management needs at the relevant time of the repurchases, which may change due to evolving circumstances. For any treasury shares of the Company deposited with CCASS pending resale on the Stock Exchange, the Company shall, upon approval by the Board, implement the below Interim Measures which include (without limitation):

(i) procuring its broker not to give any instructions to HKSCC to vote at general meetings for the treasury shares deposited with CCASS;

(ii) in the case of dividends or distributions (if any and where applicable), withdrawing the treasury shares from CCASS, and either re-register them in its own name as treasury shares or cancel them, in each case before the relevant record date for the dividend or distributions; and

(iii) taking any other measures to ensure that it will not exercise any shareholders' rights or receive any entitlements which would otherwise be suspended under the applicable laws if those Shares were registered in its own name as treasury shares.

7. TAKEOVERS CODE

If as a result of a buy-back of Shares pursuant to the Share Buy-back Mandate, a Shareholder's proportionate interest in the voting rights of the Company increases, such increase will be treated as an acquisition of voting rights for the purposes of the Takeovers Code. Accordingly, a Shareholder or a group of Shareholders acting in concert (within the meaning under the Takeovers Code), depending on the level of increase in the Shareholder's interest, could obtain or consolidate control of the Company and thereby become obliged to make a mandatory offer in accordance with Rule 26 of the Takeovers Code.

As at the Latest Practicable Date, MicroPort Scientific Investment LTD ("**MP Scientific**") held approximately 38.61% of the total number of issued Shares. MP Scientific is directly wholly owned by MicroPort Scientific Corporation ("**MicroPort**"). By virtue of SFO, MicroPort is deemed to be interested in the Shares in which MP Scientific is interested. In the event that the Directors exercised in full the power to buy back and cancel Shares in accordance with the terms of the Buyback Mandate proposed at the Annual General Meeting (if the present shareholdings remain the same), the shareholding of both MicroPort and MP Scientific would be increased to approximately 42.82% of the total number of issued Shares. The Directors consider that such increase in shareholding would give rise to an obligation to make a mandatory offer under Rule 26 of the Takeovers Code.

The Directors do not propose to exercise the Share Buy-back Mandate to such an extent as would, in the circumstances, give rise to an obligation to make a mandatory offer in accordance with Rule 26 of the Takeovers Code.

8. SHARE BUY-BACK MADE BY THE COMPANY

During the 6 months prior to the Latest Practicable Date, the Company has bought back a total of 300,000 Shares (on the Stock Exchange and the details are set out below).

		Price Per Share	
Date of Buy-back	**No. of Shares**	**Highest**	**Lowest**
		HK$	*HK$*
28 April 2026	100,000	10.33	10.26
29 April 2026	100,000	10.35	10.33
30 April 2026	100,000	10.38	10.32

MicroPort NeuroScientific Corporation

微創腦科學有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2172)

NOTICE IS HEREBY GIVEN that the annual general meeting (the "**Annual General Meeting**") of MicroPort NeuroScientific Corporation (the "**Company**") will be held at 10:00 a.m. on Wednesday, 3 June 2026 at 1601 Zhangdong Road, Zhangjiang Hi-Tech Park, Shanghai, the People's Republic of China for the following purposes:

1. To receive and consider the audited consolidated financial statements of the Company and the reports of the directors and auditors for the year ended 31 December 2025.

2. To declare and approve a final dividend of HK$0.09 per share in the capital of the Company for the year ended 31 December 2025 by way of a scrip dividend scheme with an option to elect to receive wholly or partly by an allotment and issue of shares credited as fully paid in lieu of cash payment.

3. (a) To re-elect Dr. Zhang Jie as a non-executive director of the Company.

   (b) To re-elect Mr. Xie Zhiyong as an executive director of the Company.

   (c) To re-elect Mr. Liu Xudong as a non-executive director of the Company.

   (d) To re-elect Ms. Wu Xia as a non-executive director of the Company.

   (e) To re-elect Mr. Liu Thomas A. as an independent non-executive director of the Company.

   (f) To authorize the board of directors of the Company (the "**Board**") to fix the respective directors' remuneration.

4. To re-appoint KPMG and KPMG Huazhen LLP as auditors and to authorize the Board to fix their remuneration.

5. To consider and, if thought fit, pass with or without amendments, the following resolution as an ordinary resolution:

"**THAT**:

(a) subject to paragraph (b) below, a general mandate be and is hereby generally and unconditionally given to the directors of the Company to exercise during the Relevant Period (as defined below) all the powers of the Company to buy back its shares in accordance with all applicable laws, rules and regulations;

(b) the total number of shares of the Company to be bought back pursuant to the mandate in paragraph (a) above shall not exceed 10% of the total number of issued shares of the Company (excluding treasury shares) as at the date of passing of this resolution, and if any subsequent consolidation or subdivision of shares is conducted, the maximum number of shares that may be bought back under the mandate in paragraph (a) above as a percentage of the total number of issued shares (excluding treasury shares) at the date immediately before and after such consolidation or subdivision shall be the same; and

(c) for the purposes of this resolution:

"Relevant Period" means the period from the passing of this resolution until whichever is the earliest of:

(i) the conclusion of the next annual general meeting of the Company;

(ii) the expiration of the period within which the next annual general meeting of the Company is required by the Memorandum and Articles of Association of the Company or any applicable laws to be held; and

(iii) the date on which the authority set out in this resolution is revoked or varied by an ordinary resolution of the shareholders in general meeting."

6. To consider and, if thought fit, pass with or without amendments, the following resolution as an ordinary resolution:

"**THAT**:

(a) subject to paragraph (c) below, a general mandate be and is hereby generally and unconditionally given to the directors of the Company during the Relevant Period (as defined below) to allot, issue and deal with additional shares in the capital of the Company (including any sale or transfer of treasury shares out of treasury), and to make or grant offers, agreements and options which might require the exercise of such powers;

(b) the mandate in paragraph (a) above shall authorize the directors of the Company to make or grant offers, agreements and options during the Relevant Period which would or might require the exercise of such powers after the end of the Relevant Period;

(c) the aggregate number of shares allotted or agreed conditionally or unconditionally to be allotted (including any sale or transfer of treasury shares out of treasury) by the directors pursuant to the mandate in paragraph (a) above, otherwise than pursuant to:

(i) a Rights Issue (as defined below);

(ii) the exercise of options under a share option scheme of the Company; and

(iii) any scrip dividend scheme or similar arrangement providing for the allotment of shares in lieu of the whole or part of a dividend on shares of the Company in accordance with the Memorandum and Articles of association of the Company,

shall not exceed 20% of the total number of issued shares of the Company (excluding treasury shares) as at the date of passing of this resolution, and if any subsequent consolidation or subdivision of shares is conducted, the maximum number of shares that may be issued (including any sale or transfer of treasury shares out of treasury) under the mandate in paragraph (a) above as a percentage of the total number of issued shares (excluding treasury shares) at the date immediately before and after such consolidation or subdivision shall be the same; and

(d) for the purposes of this resolution:

"Relevant Period" means the period from the passing of this resolution until whichever is the earliest of:

(i) the conclusion of the next annual general meeting of the Company;

(ii) the expiration of the period within which the next annual general meeting of the Company is required by the Memorandum and Articles of Association of the Company or any applicable laws to be held; and

(iii) the date on which the authority set out in this resolution is revoked or varied by an ordinary resolution of the shareholders in general meeting.

"Rights Issue" means an offer of shares open for a period fixed by the directors to holders of shares of the Company or any class thereof on the register on a fixed record date in proportion to their then holdings of such shares or class thereof (subject to such exclusions or other arrangements as the directors may deem necessary or expedient in relation to fractional entitlements or having regard to any restrictions or obligations under the laws of any relevant jurisdiction or the requirements of any recognized regulatory body or any stock exchange)."

7. "**THAT** conditional upon the passing of the resolutions set out in items 5 and 6 of the notice convening this meeting (the "**Notice**"), the general mandate referred to in the resolution set out in item 6 of the Notice be and is hereby extended by the addition to the aggregate number of shares which may be allotted and issued or agreed conditionally or unconditionally to be allotted and issued by the directors (including any sale or transfer of treasury shares out of treasury) pursuant to such general mandate of the number of shares bought back by the Company pursuant to the mandate referred to in resolution set out in item 5 of the Notice, provided that such amount shall not exceed 10% of the total number of issued shares (excluding treasury shares) of the Company as at the date of passing of this resolution."

By Order of the Board
MicroPort NeuroScientific Corporation
Dr. Zhang Jie
Chairman and Non-executive Director

Hong Kong, 7 May 2026

Notes:

1. All resolutions at the meeting will be taken by poll pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"). Article 19.7 of the Memorandum and Articles of Association provides that, at any general meeting a resolution put to the vote of the meeting shall be decided on a poll. According to Article 20.1 of the Memorandum and Articles of Association, every shareholder present in person or by proxy shall have one vote for each share registered in his name in the register. An explanation of the detailed procedures of conducting a poll will be provided to shareholders at the meeting. The results of the poll will be published on the websites of Hong Kong Exchanges and Clearing Limited and the Company in accordance with the Listing Rules.

2. In order to be valid, the form of proxy together with the power of attorney or other authority, if any, under which it is signed or a certified copy of that power of attorney or authority, must be deposited at the Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong not later than 10:00 a.m. on Monday, 1 June 2026 (Hong Kong time). Delivery of the form of proxy shall not preclude a shareholder of the Company from attending and voting in person at the meeting and, in such event, the instrument appointing a proxy shall be deemed to be revoked.

3. For determining the entitlement to attend and vote at the above meeting, the register of members of the Company will be closed from Friday, 29 May 2026 to Wednesday, 3 June 2026, both dates inclusive, during which period no transfer of shares will be registered. The record date for determining the entitlement to attend and vote at the above meeting is 3 June 2026. In order to be eligible to attend and vote at the meeting, unregistered holders of shares of the Company shall ensure that all transfer documents accompanied by the relevant share certificates must be lodged with the Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong for registration not later than 4:30 p.m. on Thursday, 28 May 2026 (Hong Kong time), being the last share registration date. Holders of treasury shares, if any, have no voting rights at the general meeting(s) of the Company.

4. A circular containing the explanatory statement on the ordinary resolution set out in item 5 set out in this Notice will be sent to all shareholders of the Company.

As at the date of this notice, the Board of the Company comprises Mr. Xie Zhiyong and Mr. Wang Yiqun Bruce as the executive directors; Dr. Zhang Jie, Mr. Liu Xudong and Ms. Wu Xia as the non-executive directors; Dr. Zhang Haixiao, Mr. Fan Xin, Mr. Li Zhiyong and Mr. Liu Thomas A. as the independent non-executive directors.